NeuroSense shares rise 14.77% premarket after reporting 65% death risk reduction and 14-month survival benefit in ALS trial.

NeuroSense Therapeutics (NASDAQ: NRSN) rose 14.77% in premarket trading following the announcement of extended survival data from its Phase 2b PARADIGM trial of PrimeC in ALS. The trial demonstrated a statistically significant 65% reduction in the risk of death (hazard ratio: 0.35) and a 14.3-month median survival extension for patients receiving PrimeC compared to those initially on placebo. The results, derived from long-term follow-up of 68 patients, highlight the drug’s potential as a disease-modifying therapy and strengthen its regulatory prospects. The company emphasized the clinical meaningfulness of the findings, which align with prior positive top-line results, including slowed disease progression and favorable safety. These data are expected to support advancement into late-stage development, driving investor optimism about NeuroSense’s pipeline and commercial potential.